WO2008034129A3 - Treatment of cancer or obesity with conjugated linoleic acids - Google Patents
Treatment of cancer or obesity with conjugated linoleic acids Download PDFInfo
- Publication number
- WO2008034129A3 WO2008034129A3 PCT/US2007/078641 US2007078641W WO2008034129A3 WO 2008034129 A3 WO2008034129 A3 WO 2008034129A3 US 2007078641 W US2007078641 W US 2007078641W WO 2008034129 A3 WO2008034129 A3 WO 2008034129A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- patients
- obesity
- treatment
- conjugated linoleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Abstract
The present invention discloses a method of screening cancer or obesity patients to determine whether the form of cancer or obesity they have is suitable for treatment with conjugated linoleic acids as well as treating patients for cancer based on that determination. The screening identifies patients with tumor cells with a disregulation of lipid metabolism, patients who overexpress the Thyroid Hormone Responsive Spot 14 gene, and patients who overexpress the Sterol Responsive Element Binding Protein gene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84481506P | 2006-09-15 | 2006-09-15 | |
US60/844,815 | 2006-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008034129A2 WO2008034129A2 (en) | 2008-03-20 |
WO2008034129A3 true WO2008034129A3 (en) | 2008-11-20 |
Family
ID=39184647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/078641 WO2008034129A2 (en) | 2006-09-15 | 2007-09-17 | Treatment of cancer or obesity with conjugated linoleic acids |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008034129A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110183870A1 (en) * | 2008-08-28 | 2011-07-28 | Yuanlong Pan | Gene expression profiles associated with lean phenotype and uses thereof |
US8809560B2 (en) | 2011-05-17 | 2014-08-19 | Board Of Trustees Of The University Of Arkansas | Trans-, trans-conjugated linoleic acid compositions and use thereof |
US9375433B2 (en) | 2012-09-26 | 2016-06-28 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
WO2014049071A1 (en) * | 2012-09-26 | 2014-04-03 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
US9062276B2 (en) | 2012-12-03 | 2015-06-23 | Board Of Trustees Of The University Of Arkansas | Conjugated linoleic acid rich vegetable oil production from linoleic rich oils by heterogeneous catalysis |
CN112569218A (en) * | 2020-12-21 | 2021-03-30 | 自然资源部第一海洋研究所 | Application of conjugated linoleic acid isomer in preparation of medicines and health products for reducing visceral fat content |
-
2007
- 2007-09-17 WO PCT/US2007/078641 patent/WO2008034129A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
BASU S. ET AL.: "Conjugated Linoleic Acid Induces Lipid Peroxidation in Humans", FEBS LETTERS, vol. 468, no. 1, 2000, pages 33 - 36, XP004260993 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008034129A2 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008034129A3 (en) | Treatment of cancer or obesity with conjugated linoleic acids | |
WO2007113648A3 (en) | Ctla4 antibody combination therapy | |
WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
WO2006010153A3 (en) | Lipid-amino acid conjugates and methods of use | |
WO2009038689A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
WO2008036341A3 (en) | Compositions and methods relating to glucagon receptor antibodies | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
WO2006036922A3 (en) | Srage mimetibody, compositions, methods and uses | |
MX2009005787A (en) | Methods of treating systemic lupus erythematosus. | |
MX2008009886A (en) | Antibodies that bind par-2. | |
WO2009098682A3 (en) | Methods and compositions for treatment of mitochondrial disorders | |
EP3241558A3 (en) | Highly soluble leptins | |
WO2008088854A3 (en) | Genetic markers for predicting responsiveness to combination therapy | |
WO2009070294A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof | |
WO2007111661A3 (en) | Human antibodies specific for gastrin materials and methods | |
WO2005040421A3 (en) | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues | |
WO2006031363A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2006116410A3 (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
WO2006046997A3 (en) | Process, system and method for improving the determination of digestive effects upon an ingestable substance | |
WO2008047235A3 (en) | Methods of treating disorders associated with fat storage | |
WO2009059201A3 (en) | Id2 as a target in colorectal carcinoma | |
WO2009108706A3 (en) | Methods for inhibiting six 1 and eya proteins | |
WO2007103876A3 (en) | Cancer therapeutic | |
WO2007087263A3 (en) | Human zip1, zinc and citrate for prostate cancer screening | |
WO2008147869A3 (en) | Markers and methods for assessing and treating crohn's disease and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07814885 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07814885 Country of ref document: EP Kind code of ref document: A2 |